 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| ST-2427 / SiteOne Therap
Trial termination: Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 (clinicaltrials.gov) - Aug 3, 2023
P1, N=24, Terminated, Sponsor: SiteOne Therapeutics, Inc.
Active, not recruiting --> Terminated; strategic decision
- || ST-2427 / SiteOne Therap
Enrollment closed, Trial completion date, Trial primary completion date: Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 (clinicaltrials.gov) - May 9, 2022
P1, N=30, Active, not recruiting, Sponsor: SiteOne Therapeutics, Inc.
Active, not recruiting --> Terminated; strategic decision Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- || ST-2427 / SiteOne Therap
Enrollment change, Trial completion date, Trial primary completion date: Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 (clinicaltrials.gov) - Aug 18, 2021
P1, N=30, Recruiting, Sponsor: SiteOne Therapeutics, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 N=18 --> 30 | Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Jul 2021 --> Dec 2021
- || ST-2427 / SiteOne Therap
Enrollment open: Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 (clinicaltrials.gov) - Mar 4, 2021
P1, N=18, Recruiting, Sponsor: SiteOne Therapeutics, Inc.
N=18 --> 30 | Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Jul 2021 --> Dec 2021 Not yet recruiting --> Recruiting
- | ST-2427 / SiteOne Therap
Journal: Coordination of las regulated virulence factors with Multidrug-Resistant and extensively drug-resistant in superbug strains of P. aeruginosa. (Pubmed Central) - Feb 17, 2021
In MDR-XDR strains, a strong correlation between lasI/R and the variants of antibiotic resistance genes was found. In conclusion, the pathogenicity of P. aeruginosa may increase the prevalence of antibiotic-resistant strains.
- || ST-2427 / SiteOne Therap
Enrollment change, Trial initiation date, Trial primary completion date: Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 (clinicaltrials.gov) - Jan 10, 2021
P1, N=18, Not yet recruiting, Sponsor: SiteOne Therapeutics, Inc.
In conclusion, the pathogenicity of P. aeruginosa may increase the prevalence of antibiotic-resistant strains. N=48 --> 18 | Initiation date: Sep 2020 --> Mar 2021 | Trial primary completion date: Feb 2021 --> Jun 2021
- | ST-2427 / SiteOne Therap
New P1 trial: Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 (clinicaltrials.gov) - Jul 16, 2020
P1, N=48, Not yet recruiting, Sponsor: SiteOne Therapeutics, Inc.